GRAFT POLYMER UK LS -001
Research GRAFT POLYMER UK LS -001 (J4I) on Bullrun: market cap EUR 13.61M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerJ4I
- ExchangeF
- CountryUnited Kingdom
- SectorIndustrials
- IndustrySpecialty Industrial Machinery
- CurrencyEUR
- Market capEUR 13.61M
- Financial periodFY2024
- Revenue growth-100.0%
- Net income-GBP 1.59M
- Free cash flow-GBP 1.13M
Valuation Snapshot
latest market cap is EUR 13.61M.
About GRAFT POLYMER UK LS -001
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product consists of SVN-114 for the treatment of post-traumatic stress disorder;
Frequently asked questions
What is GRAFT POLYMER UK LS -001's market cap?
GRAFT POLYMER UK LS -001's market capitalization is EUR 13.61M.
What does GRAFT POLYMER UK LS -001 do?
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder;